Literature DB >> 27697998

Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.

Heather Nesbitt1, Niall M Byrne1,2, S Nicole Williams3, Louise Ming1, Jenny Worthington1,3, Rachel J Errington4,5, Laurence H Patterson6, Paul J Smith6, Stephanie R McKeown1,6, Declan J McKenna7.   

Abstract

Purpose: To understand the role of hypoxia in prostate tumor progression and to evaluate the ability of the novel unidirectional hypoxia-activated prodrug OCT1002 to enhance the antitumor effect of bicalutamide.Experimental Design: The effect of OCT1002 on prostate cancer cells (LNCaP, 22Rv1, and PC3) was measured in normoxia and hypoxia in vitroIn vivo, tumor growth and lung metastases were measured in mice treated with bicalutamide, OCT1002, or a combination. Dorsal skin fold chambers were used to image tumor vasculature in vivo Longitudinal gene expression changes in tumors were analyzed using PCR.
Results: Reduction of OCT1002 to its active form (OCT1001) decreased prostate cancer cell viability. In LNCaP-luc spheroids, OCT1002 caused increased apoptosis and decreased clonogenicity. In vivo, treatment with OCT1002 alone, or with bicalutamide, showed significantly greater tumor growth control and reduced lung metastases compared with controls. Reestablishment of the tumor microvasculature following bicalutamide-induced vascular collapse is inhibited by OCT1002. Significantly, the upregulation of RUNX2 and its targets caused by bicalutamide alone was blocked by OCT1002.Conclusions: OCT1002 selectively targets hypoxic tumor cells and enhances the antitumor efficacy of bicalutamide. Furthermore, bicalutamide caused changes in gene expression, which indicated progression to a more malignant genotype; OCT1002 blocked these effects, emphasizing that more attention should be attached to understanding genetic changes that may occur during treatment. Early targeting of hypoxic cells with OCT1002 can provide a means of inhibiting prostate tumor growth and malignant progression. This is of importance for the design and refinement of existing androgen-deprivation regimens in the clinic. Clin Cancer Res; 23(7); 1797-808. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27697998     DOI: 10.1158/1078-0432.CCR-16-1361

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Hypoxia signaling: Challenges and opportunities for cancer therapy.

Authors:  Mircea Ivan; Melissa L Fishel; Oana M Tudoran; Karen E Pollok; Xue Wu; Paul J Smith
Journal:  Semin Cancer Biol       Date:  2021-10-07       Impact factor: 15.707

Review 2.  Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies.

Authors:  Josh W DiGiacomo; Daniele M Gilkes
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 3.  Hypoxia-activated prodrugs and redox-responsive nanocarriers.

Authors:  Yun Zeng; Jingwen Ma; Yonghua Zhan; Xinyi Xu; Qi Zeng; Jimin Liang; Xueli Chen
Journal:  Int J Nanomedicine       Date:  2018-10-18

Review 4.  Hypoxia-active nanoparticles used in tumor theranostic.

Authors:  Yaqin Wang; Wenting Shang; Meng Niu; Jie Tian; Ke Xu
Journal:  Int J Nanomedicine       Date:  2019-05-22

5.  Data pertaining to aberrant intracellular calcium handling during androgen deprivation therapy in prostate cancer.

Authors:  Debbie O'Reilly; Tim Downing; Sana Kouba; Marie Potier-Cartereau; Declan J McKenna; Christophe Vandier; Paul Buchanan
Journal:  Data Brief       Date:  2022-04-17

6.  Proteome dynamics analysis identifies functional roles of SDE2 and hypoxia in DNA damage response in prostate cancer cells.

Authors:  Ang Luo; Yao Gong; Hyungjin Kim; Yue Chen
Journal:  NAR Cancer       Date:  2020-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.